Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $122.29, but opened at $127.50. Nutex Health shares last traded at $118.99, with a volume of 93,844 shares trading hands.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on NUTX. Wall Street Zen cut shares of Nutex Health from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Benchmark lifted their price objective on Nutex Health from $150.00 to $300.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Finally, Maxim Group upped their target price on Nutex Health from $100.00 to $225.00 and gave the stock a "buy" rating in a research note on Tuesday, May 20th.
Check Out Our Latest Stock Report on NUTX
Nutex Health Stock Performance
The company has a current ratio of 2.27, a quick ratio of 2.26 and a debt-to-equity ratio of 1.02. The firm's fifty day moving average price is $135.02 and its two-hundred day moving average price is $85.19. The stock has a market capitalization of $640.32 million, a PE ratio of 9.75 and a beta of -0.04.
Nutex Health (NASDAQ:NUTX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $2.56 EPS for the quarter, beating the consensus estimate of ($0.15) by $2.71. The company had revenue of $211.79 million for the quarter, compared to analyst estimates of $81.09 million. Nutex Health had a net margin of 10.76% and a return on equity of 42.08%.
Insider Transactions at Nutex Health
In other Nutex Health news, CFO Jon Christian Bates acquired 1,000 shares of the business's stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average cost of $81.81 per share, for a total transaction of $81,810.00. Following the completion of the transaction, the chief financial officer directly owned 4,888 shares of the company's stock, valued at $399,887.28. This represents a 25.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 36.92% of the company's stock.
Institutional Investors Weigh In On Nutex Health
A number of institutional investors have recently added to or reduced their stakes in NUTX. Russell Investments Group Ltd. purchased a new position in Nutex Health during the fourth quarter valued at $672,000. Millennium Management LLC acquired a new position in shares of Nutex Health during the 4th quarter worth about $213,000. American Century Companies Inc. acquired a new position in shares of Nutex Health during the 4th quarter worth about $1,362,000. Squarepoint Ops LLC purchased a new position in Nutex Health in the 4th quarter valued at about $285,000. Finally, Northern Trust Corp acquired a new stake in Nutex Health in the 4th quarter worth about $200,000. Institutional investors and hedge funds own 5.32% of the company's stock.
About Nutex Health
(
Get Free Report)
Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.